Orchard Therapeutics (NASDAQ:ORTX) is set to release its earnings data before the market opens on Thursday, August 8th. Analysts expect Orchard Therapeutics to post earnings of ($0.36) per share for the quarter.
Orchard Therapeutics (NASDAQ:ORTX) last posted its quarterly earnings data on Tuesday, May 28th. The company reported ($0.35) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.49) by $0.14. On average, analysts expect Orchard Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Shares of Orchard Therapeutics stock traded up $0.05 during trading on Tuesday, reaching $12.75. The company’s stock had a trading volume of 816 shares, compared to its average volume of 184,592. The stock has a market capitalization of $1.11 billion and a P/E ratio of -1.25. Orchard Therapeutics has a 1-year low of $8.65 and a 1-year high of $21.64. The company has a 50-day moving average price of $13.66.
A number of research firms have recently weighed in on ORTX. ValuEngine raised Orchard Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Zacks Investment Research cut Orchard Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 31st. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $23.80.
Orchard Therapeutics Company Profile
Orchard Therapeutics plc, integrated biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified drug product to treat the patient's disease through a single administration.
See Also: What is the Fibonacci sequence?
Receive News & Ratings for Orchard Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchard Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.